TIL
Instil Bio, Inc.Company Information
- Company Name
- Instil Bio, Inc.
- CIK
- CIK0001789769
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TIL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TIL
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-09-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 30,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,904,022
- Shares outstanding
- 6,781,976
- Ownership
- 28.07%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 4.26%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 6 | 5 | 7 | 6 | 8 | 15 | 9 | 7 | 7 | 5 | 9 | 9 | ||||||
| Restricted Cash | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 2 | - | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | - | - | - | 141 | 174 | ||||||
| Available For Sale Securities Debt Securities | 64 | 70 | 69 | 74 | 84 | 88 | 105 | 114 | 142 | 148 | 141 | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 4 | 3 | 3 | 9 | 12 | 6 | 6 | 9 | 11 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | 1 | - | - | - | - | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | 112 | 112 | 112 | 0 | 112 | 0 | - | - | 1 | - | 2 | ||||||
| Assets Current | 72 | 188 | 191 | 196 | 207 | 219 | 124 | 133 | 155 | 161 | 161 | 196 | ||||||
| Property Plant And Equipment Net | 112 | 0 | 0 | 0 | 0 | 0 | 129 | 130 | 133 | 134 | 139 | 139 | ||||||
| Operating Lease Right Of Use Asset | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | ||||||
| Long Term Investments | - | - | - | 3 | 12 | 7 | 0 | 3 | 4 | 8 | 23 | - | ||||||
| Accrued Investment Income Receivable | 8 | 8 | 8 | 7 | - | - | 4 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 4 | 4 | 4 | 4 | 11 | 10 | 4 | 6 | 1 | 2 | 1 | 3 | ||||||
| Assets | 198 | 200 | 204 | 212 | 231 | 237 | 264 | 273 | 294 | 306 | 326 | 340 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities Current | 3 | 5 | 5 | 6 | 14 | 7 | 8 | 10 | 10 | 11 | 11 | 13 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | 0 | 1 | 1 | 1 | 1 | 2 | 5 | 5 | 5 | 8 | ||||||
| Operating Lease Liability Noncurrent | 2 | - | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | ||||||
| Long Term Loans Payable | 85 | 85 | 85 | 85 | 84 | 84 | 84 | 82 | 82 | 82 | 81 | 81 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 90 | 90 | 90 | 91 | 99 | 93 | 94 | 96 | 99 | 100 | 100 | 106 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 843 | 842 | 841 | 839 | 837 | 829 | 825 | 820 | 816 | 812 | 807 | 803 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -1 | -1 | -1 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -735 | -731 | -726 | -718 | -705 | -683 | -655 | -643 | -620 | -605 | -581 | -568 | ||||||
| Stockholders Equity | 107 | 111 | 114 | 120 | 132 | 145 | 169 | 176 | 195 | 206 | 226 | 234 | ||||||
| Liabilities And Stockholders Equity | 198 | 200 | 204 | 212 | 231 | 237 | 264 | 273 | 294 | 306 | 326 | 340 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Shares Outstanding | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInstil Bio, Inc. (TIL) — SEC Financial Statements & Analysis
Instil Bio, Inc. (TIL) is a biological products, (no diagnostic substances) company, incorporated in NY. Instil Bio, Inc. trades on Nasdaq as: TIL. Instil Bio, Inc. (TIL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Instil Bio, Inc. carries a market cap of $52.15M, a P/E ratio of -1.72x, a P/B ratio of 0.49x, an enterprise value of $46.36M, and an EV/EBITDA multiple of -1.26x. On profitability, it posts a Return on Equity (ROE) of -25.33%, a Return on Assets (ROA) of -14.13%, and a Return on Invested Capital (ROIC) of -32.98%. Per share, it reports EPS of $-4.46, diluted EPS of $-4.46, free cash flow per share of $-3.48, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -64.17% year-over-year and EPS growth of -65.15% year-over-year. On the balance sheet, it maintains a current ratio of 21.67x, a quick ratio of 21.16x, working capital of $68.30M, a debt-to-equity ratio of 0.84x, a debt ratio of 0.46, an interest coverage ratio of -5.92x, free cash flow of $-23.61M (TTM), and net debt of $-5.79M. Figures sourced from SEC EDGAR.
- Market Cap
- $52.15M
- P/E TTM
- -1.72x
- EPS TTM
- $-4.46
- P/B TTM
- 0.49x
- ROE TTM
- -25.33%
- ROA TTM
- -14.13%
- Debt To Equity
- 0.84x
- Free Cash Flow TTM
- $-23.61M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Instil Bio, Inc. in?
Instil Bio, Inc. (TIL) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TIL trade on?
Instil Bio, Inc. (TIL) trades on the Nasdaq.
Where is Instil Bio, Inc. incorporated?
Instil Bio, Inc. is incorporated in NY.
When was Instil Bio, Inc. (TIL)'s most recent SEC filing?
Instil Bio, Inc. (TIL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is TIL's market cap?
Instil Bio, Inc. (TIL) has a market capitalization of $52.15M as of 2026-06-30.
What is TIL's EPS (earnings per share)?
Instil Bio, Inc. (TIL)'s trailing twelve month EPS is $-4.46 as of 2026-06-30.
What is TIL's ROE (return on equity)?
Instil Bio, Inc. (TIL)'s trailing twelve month Return on Equity (ROE) is -25.33% as of 2026-06-30.
What is TIL's ROA (return on assets)?
Instil Bio, Inc. (TIL)'s trailing twelve month Return on Assets (ROA) is -14.13% as of 2026-06-30.
What is TIL's ROIC (return on invested capital)?
Instil Bio, Inc. (TIL)'s trailing twelve month Return on Invested Capital (ROIC) is -32.98% as of 2026-06-30.
What is TIL's EV/EBITDA?
Instil Bio, Inc. (TIL)'s trailing twelve month EV/EBITDA is -1.26x as of 2026-06-30.